Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.77 +11.6%	$0.77	$0.38 ▼ $115.57	$8.70M	0.71	1.63 million shs	115,767 shs
CLSD Clearside Biomedical	$0.41 +1.0%	$0.62	$0.29 ▼ $1.65	$31.97M	2.08	1.85 million shs	360,371 shs
ESLA Estrella Immunopharma	$0.97 +10.2%	$0.89	$0.63 ▼ $1.78	$35.95M	0.34	107,030 shs	4,629 shs
OKUR OnKure Therapeutics	$2.83 +4.4%	$2.40	$1.70 ▼ $20.00	$38.23M	0.4	112,859 shs	59,578 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-0.62%	-11.54%	-14.18%	+29.21%	-99.01%
CLSD Clearside Biomedical	-1.13%	-10.22%	+14.68%	-53.30%	-60.10%
ESLA Estrella Immunopharma	-4.66%	+1.73%	+0.69%	-15.38%	-37.59%
OKUR OnKure Therapeutics	-0.73%	+1.50%	+20.98%	+26.05%	+270,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEON AEON Biopharma	2.8732 of 5 stars	3.5	5.0	0.0	0.0	1.9
CLSD Clearside Biomedical	2.225 of 5 stars	4.1	3.0	1.7	0.0	0.0
ESLA Estrella Immunopharma	2.8389 of 5 stars	3.5	5.0	1.9	1.7	0.0
OKUR OnKure Therapeutics	3.1939 of 5 stars	3.6	0.0	2.7	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	48,092.77% Upside
CLSD Clearside Biomedical	2.17	Hold	$4.20	934.48% Upside
ESLA Estrella Immunopharma	3.00	Buy	$16.00	1,611.23% Upside
OKUR OnKure Therapeutics	3.14	Buy	$32.33	1,045.76% Upside

Current Analyst Ratings Breakdown

Latest AEON, OKUR, ESLA, and CLSD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	OKUR OnKure Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
5/29/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
CLSD Clearside Biomedical	$4.17M	7.65	N/A	N/A	($0.62) per share	-0.65
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$5.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$6.08	4.14	N/A	N/A	N/A	N/A	-994.63%	N/A
CLSD Clearside Biomedical	-$34.35M	-$0.37	N/A	N/A	N/A	-665.19%	N/A	-124.15%	N/A
ESLA Estrella Immunopharma	N/A	-$0.26	N/A	∞	N/A	N/A	-1,132.38%	-358.54%	9/26/2025 (Estimated)
OKUR OnKure Therapeutics	-$52.67M	-$4.80	N/A	N/A	N/A	N/A	-60.52%	-55.43%	11/6/2025 (Estimated)

Latest AEON, OKUR, ESLA, and CLSD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	OKUR OnKure Therapeutics	-$1.23	-$1.14	+$0.09	-$1.14	N/A	N/A
8/8/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	-$0.06	+$0.06	-$0.06	$0.50 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
CLSD Clearside Biomedical	N/A	3.87	3.87
ESLA Estrella Immunopharma	N/A	0.16	0.16
OKUR OnKure Therapeutics	N/A	11.13	11.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
CLSD Clearside Biomedical	18.75%
ESLA Estrella Immunopharma	0.35%
OKUR OnKure Therapeutics	90.98%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
CLSD Clearside Biomedical	6.70%
ESLA Estrella Immunopharma	55.10%
OKUR OnKure Therapeutics	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.31 million	74.37 million	Not Optionable
CLSD Clearside Biomedical	30	78.51 million	73.25 million	Optionable
ESLA Estrella Immunopharma	N/A	37.07 million	16.64 million	Not Optionable
OKUR OnKure Therapeutics	N/A	13.51 million	13.20 million	N/A

AEON, OKUR, ESLA, and CLSD Headlines

Recent News About These Companies

Brokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) PT at $32.33

August 22 at 2:15 AM | americanbankingnews.com

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

August 19 at 7:44 AM | finance.yahoo.com

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

August 19 at 7:44 AM | finance.yahoo.com

Leerink Partnrs Has Positive Forecast for OKUR Q3 Earnings

August 16, 2025 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and AbCellera Biologics (ABCL)

August 15, 2025 | theglobeandmail.com

OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)

August 12, 2025 | msn.com

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

August 12, 2025 | globenewswire.com

OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

OKUR OnKure Therapeutics, Inc.

June 12, 2025 | seekingalpha.com

Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position

June 3, 2025 | tipranks.com

Insider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of Stock

May 20, 2025 | insidertrades.com

OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 Shares

May 15, 2025 | insidertrades.com

Major Shareholder Sells Thousands of OnKure Therapeutics Shares!

May 14, 2025 | tipranks.com

Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics

May 9, 2025 | tipranks.com

OnKure increased R&D spending in 1Q with drug trials underway

May 7, 2025 | bizwest.comB

OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | finanznachrichten.de

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | globenewswire.com

OnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock News

April 30, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AEON, OKUR, ESLA, and CLSD Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.77 +0.08 (+11.58%)

Closing price 04:00 PM Eastern

Extended Trading

$0.76 -0.01 (-1.16%)

As of 04:04 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Clearside Biomedical NASDAQ:CLSD

$0.41 +0.00 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 -0.01 (-2.75%)

As of 04:49 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Estrella Immunopharma NASDAQ:ESLA

$0.97 +0.09 (+10.22%)

Closing price 03:59 PM Eastern

Extended Trading

$0.90 -0.07 (-7.62%)

As of 04:10 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

OnKure Therapeutics NASDAQ:OKUR

$2.83 +0.12 (+4.43%)

Closing price 04:00 PM Eastern

Extended Trading

$2.83 0.00 (0.00%)

As of 04:51 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time